Literature DB >> 28497377

[Choosing wisely recommendations in hematology and oncology].

S W Krause1, A Neubauer2.   

Abstract

Many new diagnostic and therapeutic options have been introduced in the field of hematology and medical oncology during recent years. Rational treatment recommendations are thus of even greater importance. Five presumably underused measures are recommended (positive recommendations), primarily pertaining to supportive therapy, but also concerning the selective use of molecular diagnostics. Recommendations to avoid unnecessary procedures (negative recommendations) involve a possible excessive use of anticancer therapy and imaging, and insufficiently selective use of growth factors, antiemetics, and targeted therapies.

Entities:  

Keywords:  Medical overuse; Molecular targeted therapy; Narrative medicine; Pain therapy; Underuse, health services

Mesh:

Substances:

Year:  2017        PMID: 28497377     DOI: 10.1007/s00108-017-0249-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  20 in total

1.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

Authors:  Thomas J Smith; James Khatcheressian; Gary H Lyman; Howard Ozer; James O Armitage; Lodovico Balducci; Charles L Bennett; Scott B Cantor; Jeffrey Crawford; Scott J Cross; George Demetri; Christopher E Desch; Philip A Pizzo; Charles A Schiffer; Lee Schwartzberg; Mark R Somerfield; George Somlo; James C Wade; James L Wade; Rodger J Winn; Antoinette J Wozniak; Antonio C Wolff
Journal:  J Clin Oncol       Date:  2006-05-08       Impact factor: 44.544

Review 2.  Antiemetics: American Society of Clinical Oncology clinical practice guideline update.

Authors:  Ethan Basch; Ann Alexis Prestrud; Paul J Hesketh; Mark G Kris; Petra C Feyer; Mark R Somerfield; Maurice Chesney; Rebecca Anne Clark-Snow; Anne Marie Flaherty; Barbara Freundlich; Gary Morrow; Kamakshi V Rao; Rowena N Schwartz; Gary H Lyman
Journal:  J Clin Oncol       Date:  2011-09-26       Impact factor: 44.544

3.  A validation study of the WHO method for cancer pain relief.

Authors:  V Ventafridda; M Tamburini; A Caraceni; F De Conno; F Naldi
Journal:  Cancer       Date:  1987-02-15       Impact factor: 6.860

4.  Routine Imaging for Diffuse Large B-Cell Lymphoma in First Complete Remission Does Not Improve Post-Treatment Survival: A Danish-Swedish Population-Based Study.

Authors:  Tarec Christoffer El-Galaly; Lasse Hjort Jakobsen; Martin Hutchings; Peter de Nully Brown; Herman Nilsson-Ehle; Elisabeth Székely; Karen Juul Mylam; Viktoria Hjalmar; Hans Erik Johnsen; Martin Bøgsted; Mats Jerkeman
Journal:  J Clin Oncol       Date:  2015-10-05       Impact factor: 44.544

5.  Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis.

Authors:  Barbara F Eichhorst; Kirsten Fischer; Anna-Maria Fink; Thomas Elter; Clemens M Wendtner; Valentin Goede; Manuela Bergmann; Stephan Stilgenbauer; Georg Hopfinger; Matthias Ritgen; Jasmin Bahlo; Raymonde Busch; Michael Hallek
Journal:  Blood       Date:  2010-12-07       Impact factor: 22.113

6.  Patients' expectations about effects of chemotherapy for advanced cancer.

Authors:  Jane C Weeks; Paul J Catalano; Angel Cronin; Matthew D Finkelman; Jennifer W Mack; Nancy L Keating; Deborah Schrag
Journal:  N Engl J Med       Date:  2012-10-25       Impact factor: 91.245

Review 7.  A systematic review of physicians' survival predictions in terminally ill cancer patients.

Authors:  Paul Glare; Kiran Virik; Mark Jones; Malcolm Hudson; Steffen Eychmuller; John Simes; Nicholas Christakis
Journal:  BMJ       Date:  2003-07-26

8.  Statistical illiteracy undermines informed shared decision making.

Authors:  Wolfgang Gaissmaier; Gerd Gigerenzer
Journal:  Z Evid Fortbild Qual Gesundhwes       Date:  2008

9.  Patient involvement in decisions to limit treatment: the crucial role of agreement between physician and patient.

Authors:  Eva C Winkler; Stella Reiter-Theil; Dorothee Lange-Riess; Nina Schmahl-Menges; Wolfgang Hiddemann
Journal:  J Clin Oncol       Date:  2009-03-23       Impact factor: 44.544

Review 10.  American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.

Authors:  Carmen J Allegra; J Milburn Jessup; Mark R Somerfield; Stanley R Hamilton; Elizabeth H Hammond; Daniel F Hayes; Pamela K McAllister; Roscoe F Morton; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.